Table 2.
Baseline Biomarkers and Gene Polymorphisms
| CEE+MPA Trial | CEE Trial | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | CHD | Control | CHD | P-value2 | ||||||||||
| N | Median | IQR1 | N | Median | IQR | N | Median | IQR | N | Median | IQR | |||
| C-reactive protein (ug/ml) | 464 | 1.8 | 3.5 | 198 | 2.9 | 4.2 | 326 | 2.6 | 3.6 | 149 | 3.7 | 5.5 | <0.001 | |
| E-selectin (ng/ml) | 471 | 43.0 | 26.0 | 196 | 45.5 | 27.5 | 329 | 45.0 | 27.0 | 147 | 47.0 | 34.0 | 0.08 | |
| IL-6 (pg/ml) | 471 | 2.8 | 2.2 | 196 | 3.4 | 2.3 | 324 | 2.8 | 2.3 | 152 | 3.7 | 3.7 | <0.001 | |
| MMP-9 (ng/ml) | 482 | 217.5 | 148.0 | 205 | 228.0 | 168.0 | 335 | 217.0 | 148.0 | 154 | 235.0 | 177.0 | 0.01 | |
| HDL cholesterol (mg/dl) | 481 | 54.0 | 20.0 | 202 | 48.0 | 15.0 | 334 | 52.0 | 17.0 | 152 | 47.0 | 17.0 | <0.001 | |
| LDL cholesterol (mg/dl) | 473 | 138.0 | 44.0 | 194 | 151.0 | 41.0 | 327 | 140.0 | 47.0 | 146 | 149.0 | 46.0 | <0.001 | |
| Total cholesterol (mg/dl) | 482 | 221.0 | 49.0 | 204 | 235.0 | 44.5 | 335 | 228.0 | 51.0 | 154 | 232.5 | 52.0 | <0.001 | |
| Triglyceride (mg/dl) | 482 | 130.0 | 82.0 | 204 | 145.0 | 107.5 | 335 | 142.0 | 90.0 | 154 | 162.0 | 101.0 | <0.001 | |
| Lp (a) (mg/dl) | 459 | 18.0 | 28.0 | 194 | 22.0 | 37.0 | 320 | 23.0 | 34.0 | 147 | 22.0 | 35.0 | 0.15 | |
| D-dimer (ug/ml) | 481 | 0.3 | 0.3 | 202 | 0.4 | 0.4 | 334 | 0.3 | 0.3 | 153 | 0.4 | 0.4 | <0.001 | |
| Fibrinogen (mg/dl) | 481 | 305.0 | 112.0 | 202 | 317.0 | 123.0 | 334 | 313.5 | 125.0 | 154 | 332.0 | 128.0 | <0.001 | |
| Factor VIII (%) | 480 | 105.0 | 61.0 | 202 | 120.0 | 74.0 | 334 | 103.0 | 68.0 | 154 | 117.5 | 77.0 | <0.001 | |
| PAI – 1 antigen (ng/ml) | 454 | 35.4 | 46.4 | 187 | 41.3 | 47.4 | 308 | 43.6 | 57.4 | 142 | 47.8 | 51.7 | 0.54 | |
| Prothrombin F1.2 (nmol/L) | 448 | 1.3 | 0.4 | 185 | 1.3 | 0.5 | 306 | 1.3 | 0.5 | 142 | 1.4 | 0.6 | 0.09 | |
| PAP (nmol/L) | 453 | 4.5 | 2.5 | 187 | 4.5 | 2.3 | 308 | 4.2 | 2.1 | 142 | 4.3 | 2.4 | 0.51 | |
| TAFI conc (ug/ml) | 470 | 5.1 | 2.5 | 200 | 4.9 | 2.6 | 327 | 5.2 | 2.7 | 146 | 5.2 | 1.9 | 0.35 | |
| vWF (%) | 479 | 93.0 | 54.0 | 202 | 97.0 | 64.0 | 333 | 89.0 | 52.0 | 153 | 100.0 | 61.0 | <0.001 | |
| Leukocyte count (Kcell/ml) | 482 | 5.8 | 1.9 | 202 | 6.3 | 2.3 | 335 | 5.7 | 2.1 | 153 | 6.4 | 2.3 | <0.001 | |
| Platelet count (Kcell/ml) | 481 | 246.0 | 80.0 | 202 | 246.5 | 75.0 | 335 | 242.0 | 69.0 | 153 | 244.0 | 82.0 | 0.76 | |
| Hematocrit (%) | 482 | 40.3 | 3.7 | 200 | 41.4 | 3.7 | 334 | 40.6 | 3.8 | 152 | 41.0 | 4.5 | 0.04 | |
| Homocysteine (umol/L) | 481 | 8.1 | 3.4 | 204 | 8.4 | 3.9 | 335 | 8.3 | 3.9 | 154 | 8.5 | 4.0 | 0.003 | |
| Glucose (mg/dl) | 480 | 96.5 | 16.0 | 202 | 100.0 | 24.0 | 332 | 98.0 | 18.0 | 153 | 102.0 | 32.0 | <0.001 | |
| Insulin (UIU/ml) | 451 | 7.10 | 6.7 | 191 | 9.20 | 8.0 | 316 | 8.5 | 8.4 | 136 | 10.0 | 9.6 | <0.001 | |
| N | % | N | % | N | % | N | % | |||||||
| ER Beta - 1730 A/G | CC | 176 | 38.7 | 67 | 34.2 | 118 | 37.1 | 52 | 36.1 | 0.67 | ||||
| CT | 216 | 47.5 | 101 | 51.5 | 155 | 48.7 | 71 | 49.3 | ||||||
| TT | 63 | 13.8 | 28 | 14.3 | 45 | 14.2 | 21 | 14.6 | ||||||
| Factor V Leiden | GG | 430 | 95.3 | 192 | 96.0 | 315 | 96.0 | 144 | 97.3 | 0.39 | ||||
| GA | 21 | 4.7 | 8 | 4.0 | 13 | 4.0 | 4 | 2.7 | ||||||
| Factor XIII val34Leu | val/val | 244 | 54.1 | 111 | 55.5 | 196 | 59.8 | 89 | 59.7 | 0.62 | ||||
| val/leu | 179 | 39.7 | 77 | 38.5 | 117 | 35.7 | 48 | 32.2 | ||||||
| leu/leu | 28 | 6.2 | 12 | 6.0 | 15 | 4.6 | 12 | 8.1 | ||||||
| GP1bαThr145Met | CC | 386 | 84.6 | 165 | 84.2 | 237 | 74.3 | 118 | 82.5 | 0.42 | ||||
| CT | 62 | 13.6 | 30 | 15.3 | 76 | 23.8 | 21 | 14.7 | ||||||
| TT | 8 | 1.8 | 1 | 0.5 | 6 | 1.9 | 4 | 2.8 | ||||||
| MTHFR | CC | 192 | 42.3 | 96 | 48.0 | 162 | 49.4 | 65 | 43.3 | 0.99 | ||||
| CT | 198 | 43.6 | 83 | 41.5 | 139 | 42.4 | 65 | 43.3 | ||||||
| TT | 64 | 14.1 | 21 | 10.5 | 27 | 8.2 | 20 | 13.3 | ||||||
| Plasminogen Activator Inhibitor | 4G4G | 111 | 25.1 | 51 | 26.0 | 65 | 20.1 | 38 | 26.6 | 0.39 | ||||
| 4G5G | 236 | 53.3 | 107 | 54.6 | 170 | 52.5 | 70 | 49.0 | ||||||
| 5G5G | 96 | 21.7 | 38 | 19.4 | 89 | 27.5 | 35 | 24.5 | ||||||
| Prothrombin 20210 | GG | 434 | 96.0 | 195 | 98.0 | 321 | 97.9 | 147 | 99.3 | 0.10 | ||||
| AG | 18 | 4.0 | 4 | 2.0 | 7 | 2.1 | 1 | 0.7 | ||||||
| Glycoprotein IIIa leu33pro | CC | 13 | 2.8 | 2 | 1.0 | 10 | 3.1 | 2 | 1.4 | |||||
| CT | 93 | 20.4 | 69 | 35.2 | 83 | 36.0 | 47 | 32.4 | <0.001 | |||||
| TT | 351 | 76.8 | 125 | 63.8 | 226 | 70.8 | 96 | 66.2 | ||||||
1
Inter-quartile range (75th percentile-25h percentile) is a non-parametric measure of data variability.
2
P-value quantifies marginal association of biomarker with incident CHD. Obtained from a logistic regression model, adjusted for treatment assignment (CEE, CEE placebo, E+P, E+P placebo, using a 1 degree-of-freedom test for association of biomarkers (log scale) and 1–2 degrees-of-freedom test for polymophisms.